Eulysis - Investment Opportunity - SVS innovation doubles pharmaceutical access at half cost globally

KENSINGTON, U.K. - July 27, 2016 - PRLog -- Eulysis Inc. was formed in the United Kingdom in February 2010 to develop and commercialize the Single Vial System (SVS) technology. Our SVS technology has been acclaimed by the WHO, Bill & Melinda Gates Foundation, Doctors Without Borders, UNICEF and others while our Founder Ross Tsakas has been acclaimed by Forbes and Bloomberg. The technology is currently months away from market launch and raising a final round of investment (Series A) currently through its investment handler, STFIH Group.

Eulysis Inc. is raising $1.75-$7.5 million to complete its remaining product development and achieve commercial pilot scale production of the SVS technology. In due course, the company will finalize negotiations with one of the three major multinational pharmaceutical companies from the UK, USA and Japan. We anticipate returns on investment being generated as soon as the end of 2017, upon completion of successful internal pilot studies with partner pharmaceutical manufacturers.

Currently, Eulysis Inc. is a subsidiary of SVS Medical LLC, acquired in 2016, with the intention of expanding into the US market and beyond. The company has valid and strong IP until 2037 in the US market and is actively in advanced negotiations with major multinational corporations to license and manufacture the SVS globally. We are not actively seeking new partners from the pharmaceutical industry at the moment but will provide updates as needed.

For more information on the Eulysis Inc. opportunities available, please visit www.svsmedical.com/eulysis-inc.html.